학술논문

waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies.
Document Type
Article
Source
Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS7595-TPS7595, 1p
Subject
Language
ISSN
0732183X